ArticleBreast cancer research and treatment2025

Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study.

Renata Colombo Bonadio et al.PubMed ↗Publisher ↗

No numbers read from the abstract.